EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plasma Biomarkers in the Distinction of Alzheimer’s Disease and Frontotemporal Dementia

Estrella Gómez-Tortosa iD, Pablo Agüero-Rabes, Alicia Ruiz-González, Sonia Wagner-Reguero, Raquel Téllez, Ignacio Mahillo iD, Andrea Ruiz-Calvo, María José Sainz, Anna Lena Nystrom, Teodoro Del Ser iD, Pascual Sánchez-Juan

International Journal of Molecular Sciences · 30.01.2025 · 26 (3) · 1231

DOI: 10.3390/ijms26031231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.01.2025. Verfasst von Estrella Gómez-Tortosa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Fundación Jiménez Díaz, 28040 Madrid, Spain. Hauptthemen laut MEDLINE: Frontotemporal Dementia, Alzheimer Disease, Biomarkers. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundacion hna, FEDER funds, Fundación Tatiana Pérez de Guzmán el Bueno.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasma biomarkers are promising tools for the screening and diagnosis of dementia in clinical settings. We analyzed plasma levels of Alzheimer’s core biomarkers, neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP), through single-molecule Array in 108 patients with Alzheimer’s (AD, cerebrospinal fluid with an amyloid+ tau+ neurodegeneration+ profile), 73 patients with frontotemporal dementia (FTD, 24 with genetic diagnosis), and 54 controls. The best area under the curve (AUC) was used to assess the discriminative power. Patients with AD had lower Aß42/40 ratios and NfL levels, along with higher levels of p-tau181 and GFAP, compared with FTD patients. Single biomarkers discriminated well between dementia patients and controls: the Aß42/40 ratio (AUC:0.86) or GFAP (AUC:0.83) was found for AD, and the NfL (AUC:0.84) was found for FTD patients. However, a combination of two (NfL with p-tau181, or the GFAP/NfL ratio, AUCs ~0.87) or three biomarkers (NfL, P-tau181, and Aß42/40 ratio, AUC: 0.90) was required to distinguish between AD and FTD. Biomarker profiles were similar across different FTD phenotypes, except for carriers of PGRN mutations, who had higher levels of NfL than C9orf72 expansion carriers. In our series, NfL alone provided the best distinction between FTD and controls, while a combination of two or three biomarkers was required to obtain good discrimination between AD and FTD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Frontotemporal DementiaAlzheimer DiseaseBiomarkersHumansMaleFemaleAgedMiddle Agedtau ProteinsNeurofilament ProteinsAmyloid beta-PeptidesGlial Fibrillary Acidic ProteinDiagnosis, DifferentialCase-Control Studies

Stichwörter der Autor:innen

Alzheimer’s diseaseSIMOAfrontotemporal dementiaglial fibrillary acid proteinneurofilament light chainplasma biomarkers

Substanzen

Biomarkerstau ProteinsNeurofilament ProteinsAmyloid beta-PeptidesGlial Fibrillary Acidic Proteinneurofilament protein LGFAP protein, human

Autor:innen und Institutionen

  • Department of Neurology, Fundación Jiménez Díaz, 28040 Madrid, Spain.
  • Instituto de Investigación Sanitaria, Fundación Jiménez Díaz (IIS-FJD), 28040 Madrid, Spain.
  • Alzheimer's Centre Reina Sofía-CIEN Foundation, Instituto de Salud Carlos III, 28031 Madrid, Spain.
  • Department of Immunology, Fundación Jiménez Díaz, 28040 Madrid, Spain.
  • Department of Biostatistics and Epidemiology, Fundación Jiménez Díaz, 28040 Madrid, Spain.

ORCID-Profile: Estrella Gómez-Tortosa, Ignacio Mahillo, Teodoro Del Ser

Förderung

  • Fundacion hna
  • FEDER funds
  • Fundación Tatiana Pérez de Guzmán el Bueno
  • Fundación hna
  • Ayuda a Neurociencias de la Fundación Tatiana Pérez de Guzmán el Bueno
  • FEDER funds, Spain

Zitieren

APA

Gómez-Tortosa, E., Agüero-Rabes, P., Ruiz-González, A., Wagner-Reguero, S., Téllez, R., Mahillo, I., Ruiz-Calvo, A., Sainz, M. J., Nystrom, A. L., Del Ser, T., & Sánchez-Juan, P. (2025). Plasma Biomarkers in the Distinction of Alzheimer’s Disease and Frontotemporal Dementia. International Journal of Molecular Sciences, 26(3), 1231. https://doi.org/10.3390/ijms26031231

Vancouver

Gómez-Tortosa E, Agüero-Rabes P, Ruiz-González A, Wagner-Reguero S, Téllez R, Mahillo I, et al. Plasma Biomarkers in the Distinction of Alzheimer’s Disease and Frontotemporal Dementia. International Journal of Molecular Sciences. 2025;26(3):1231. doi:10.3390/ijms26031231

BibTeX
@article{GmezTortosa2025,
  author = {Gómez-Tortosa, Estrella and Agüero-Rabes, Pablo and Ruiz-González, Alicia and Wagner-Reguero, Sonia and Téllez, Raquel and Mahillo, Ignacio and Ruiz-Calvo, Andrea and Sainz, María José and Nystrom, Anna Lena and Del Ser, Teodoro and Sánchez-Juan, Pascual},
  title = {Plasma Biomarkers in the Distinction of Alzheimer’s Disease and Frontotemporal Dementia},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {3},
  pages = {1231},
  doi = {10.3390/ijms26031231}
}
Kostenlos starten →